Greenway Greenhouse Cannabis Corporation cultivates, processes, and sells dried cannabis flower and kief. The company faces significant concerns, including a low gross margin of 12.5% and a negative net margin of -29.6%, indicating profitability challenges. Additionally, a current ratio of 0.46 and quick ratio of 0.18 suggest liquidity issues, while a high debt-to-equity ratio of 2.17 raises leverage concerns. Overall, while the cannabis sector holds potential, GWAY.CN's financial health appears weak, warranting caution for investors.
Loading financial metrics...
Gross profit margin declined from 26.3% to 7.0% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-3.1M over the last year, representing 37.9% of revenue.
Debt of $15.5M is 13.7x the company's cash position of $1.1M.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (June 30, 2026)